THE SITE OF ACTIVATION OF FACTOR-X BY CANCER PROCOAGULANT

被引:39
作者
GORDON, SG
MOURAD, AM
机构
[1] UNIV COLORADO,HLTH SCI CTR,COLORADO CANC CTR,DENVER,CO 80262
[2] EL MINIA COLL MED,DEPT BIOCHEM,MENIA,EGYPT
关键词
FACTOR-X; BLOOD COAGULATION; CANCER; BLOOD COAGULATION FACTORS; PROTEINASE; CYSTEINE PROTEINASE; PROCOAGULANTS;
D O I
10.1097/00001721-199112000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer procoagulant (CP) is a cysteine proteinase found in a variety of malignant cells and tissues and in human amnion-chorion tissue. It initiates coagulation by activating factor X. However, the amino acid sequence of the substrate protein that determines the cleavage site of cysteine proteinases is different from that of the serine proteinases that normally activate factor X, such as factor IXa, VIIa and Russell's Viper Venom (RVV). Therefore, it was of interest to determine the site of cleavage of human factor X by CP. Purified CP was incubated with purified factor X and the reaction mixture was electrophoresed on a 10% Tris-tricine SDS-PAGE gel. The proteins were electroeluted on to a polyvinylidene difluoride (PVDF) membrane, and stained with Coomassie blue. The heavy chain of activated factor X was cut out of the PVDF membrane and sequenced with an Applied Biosystems 477A with on-line HPLC. The primary cleavage sequence was Asp-Ala-Ala-Asp-Leu-Asp-Pro-; two other secondary sequences Ser-Ile-Thr-Trp-Lys-Pro- and Glu-Asn-Pro-Phe-Asp-Leu were found. The penultimate amino acid on the carbonyl side of the hydrolysed amide bond plays a critical role for the recognition of the cleavage site of cysteine proteinases. These data indicate that the penultimate amino acid for the primary, cleavage site of factor X by CP is proline-20 and for the secondary sites, proline-13 and proline-28. This is in contrast to arginine-52 that determines the specificity of the cleavage by normal serine proteinase activation. These data confirm the direct activation of factor X by CP and suggest that CP may be a new type of cysteine proteinase.
引用
收藏
页码:735 / 739
页数:5
相关论文
共 24 条
[1]   PROTEOLYSIS, FIBRINOLYSIS, AND COAGULATION - SIGNIFICANCE IN THROMBOLYTIC THERAPY [J].
ALEXANDER, B ;
KLIMAN, A ;
PECHET, L .
CIRCULATION, 1962, 26 (04) :596-&
[2]  
BARRETT AJ, 1981, METHOD ENZYMOL, V80, P536
[3]  
BARRETT AJ, 1984, S BIOL HUNG, V25, P213
[4]   ALTERED COAGULABILITY IN CANCER-PATIENTS [J].
CAPRINI, JA ;
SENER, SF .
CA-A CANCER JOURNAL FOR CLINICIANS, 1982, 32 (03) :162-172
[5]  
CARSON SD, 1987, BLOOD, V70, P490
[6]  
DONATI MB, 1986, CANCER RES, V46, P6471
[7]   THROMBOSIS AND CANCER [J].
DVORAK, HF .
HUMAN PATHOLOGY, 1987, 18 (03) :275-284
[8]   INHIBITION OF CANCER PROCOAGULANT BY PEPTIDYL DIAZOMETHYL KETONES AND PEPTIDYL SULFONIUM SALTS [J].
FALANGA, A ;
SHAW, E ;
DONATI, MB ;
CONSONNI, R ;
BARBUI, T ;
GORDON, S .
THROMBOSIS RESEARCH, 1989, 54 (05) :389-398
[9]   ISOLATION AND CHARACTERIZATION OF CANCER PROCOAGULANT - A CYSTEINE PROTEINASE FROM MALIGNANT-TISSUE [J].
FALANGA, A ;
GORDON, SG .
BIOCHEMISTRY, 1985, 24 (20) :5558-5567
[10]   COMPARISON OF PROPERTIES OF CANCER PROCOAGULANT AND HUMAN AMNION-CHORION PROCOAGULANT [J].
FALANGA, A ;
GORDON, SG .
BIOCHIMICA ET BIOPHYSICA ACTA, 1985, 831 (01) :161-165